Clinical Practitioners Advisory Committee - Entity Description

In July 1984, the AVMA Executive Board acted to discontinue the Drug Availability Committee that had functioned on an ad hoc basis since 1977. In October 1984, the Executive Board established the Drug Availability Advisory Committee and prescribed its functions and objectives. The Executive Board acted in April 1990 to change the name to the Drug Advisory Committee and modified the Committee's charge to reflect its continued mission. In November 2000, the Executive Board approved a recommendation to change the Drug Advisory Committee's name to the Clinical Practitioners Advisory Committee to more adequately describe its membership and purpose in advising the Council on Biologic and Therapeutic Agents.

Charge/Objective

To serve as an advisory committee to the Council on Biologic and Therapeutic Agents and insure wide species-based, veterinary practitioner input on issues of biologic and therapeutic agents including but not limited to drug availability, distribution, use and residue control, and on quality assurance for products of food animal origin.

Membership, Representation, and Method of Appointment

The Committee will consist of members who are representatives from the Council on Biologic and Therapeutic Agents, the American Animal Hospital Association, the American Association of Avian Pathologists, the American Association of Bovine Practitioners, the American Association of Equine Practitioners, the American Association of Small Ruminant Practitioners, the American Association of Swine Veterinarians, the American Association of Feline Practitioners, aquaculture and seafood medicine, and zoo and wildlife medicine .

Each organization represented on CPAC, except COBTA, will nominate two clinical practitioners to serve as its representative and alternate representative. The alternate representative will serve when the primary representative is unavailable. The AVMA Executive Board will consider and appoint the representative for each organization, but may reject a nominee for cause and request the nominating organization to nominate another member.

The AVMA Executive Board will appoint the primary and alternate representative for aquaculture and seafood medicine from among nominees submitted by AVMA constituent organizations and for zoo and wildlife medicine from among nominees solicited from the American Association of Zoo Veterinarians and the American Association of Wildlife Veterinarians.

Appointments of all representatives, except the representative from COBTA, will be for three years, but any represented organization may request that its representative be terminated early and nominate a replacement to fill the unexpired term. Representatives may serve a maximum of two 3-year terms. Each year, COBTA will appoint its representative and an alternate representative for a one- year term.

An advisor from the Animal Health Institute, Environmental Protection Agency, Food and Drug Administration-Center for Veterinary Medicine, U.S. Department of Agriculture-Animal and Plant Health Inspection Service, and the U.S. Department of Agriculture-Food Safety and Inspection Service are also invited to attend the meetings.

Staff Consultant: Lynne White-Shim

Chair

The member of the Council on Biologic and Therapeutic Agents will serve as Chair of the Clinical Practitioners Advisory Committee.

Meetings

The committee meets twice per year, prior to and in conjunction with the meetings of the Council on Biologic and Therapeutic Agents. Meeting agendas are established by the Committee Chair.

Funding

Travel expenses for committee members will be reimbursed in accordance with the AVMA travel policy and they will be accounted for in a separate line item in the AVMA budget. Advisors to the committee are reimbursed for expenses by the organizations they represent.

Reports

The Committee reports it activities and makes recommendations for action to the Council on Biologic and Therapeutic Agents.

Life Expectancy

The Committee will be reviewed in compliance with AVMA governance policies

10/29/02